BioInvent to Present Pipeline Progress on BI-1910 and BT-001 at ESMO
BioInvent to Present Pipeline Progress on BI-1910 and BT-001 at ESMO
LUND, SWEDEN / ACCESSWIRE / July 22, 2024 / BioInvent International (STO:BINV)
瑞典隆德/ACCESSWIRE/2024 年 7 月 22 日/BioInvent International (STO: BINV)
-
Two posters to be presented on early clinical projects from BioInvent's robust pipeline totaling six clinical programs:
Progress with the Phase 1 trial studying BI-1910 as single agent in solid tumors
Initial clinical data from the BT-001 Phase 1 study evaluating the candidate both as single agent and in combination with KEYTRUDA (pembrolizumab) in patients with solid tumors
European Society for Medical Oncology (ESMO 2024) to be held September 13-17, 2024
-
将发布两张海报,介绍BioInvent强大的产品线中的早期临床项目,总共六个临床项目:
研究 BI-1910 作为实体瘤单一药物的 1 期试验的进展
Bt-001 1期研究的初步临床数据评估了该候选药物作为单一药物以及与KEYTRUDA(pembrolizumab)联合治疗实体瘤患者
欧洲肿瘤内科学会 (ESMO 2024) 将于 2024 年 9 月 13 日至 17 日举行
BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, announced abstracts for BI-1910 and BT-001 have been selected for presentation at ESMO 2024, being held in Barcelona, Spain from September 13th to 17th, 2024.
BioInvent International Ab(“BioInvent”)(纳斯达克斯德哥尔摩股票代码:binV)是一家专注于发现和开发用于癌症免疫疗法的新型和同类首创免疫调节抗体的生物技术公司,宣布的 BI-1910 和Bt-001摘要已入选2024年9月13日至17日在西班牙巴塞罗那举行的ESMO 2024上发表。
BI-1910 is a monoclonal antibody, a TNFR2 agonist, currently enrolling patients in the monotherapy part of the ongoing Phase 1/2a study in patients with advanced solid tumors. BT-001, an anti-CTLA-4 oncolytic virus, is in Phase 1b studies in combination with MSD's (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy KEYTRUDA (pembrolizumab), in collaboration with BioInvent's partner, Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer.
BI-1910 是一种单克隆抗体,是一种 TNFR2 激动剂,目前正在进行的晚期实体瘤患者的 1/2a 期研究的单一疗法部分正在进行中。抗CTLA-4溶瘤病毒Bt-001与BioInvent的合作伙伴Transgene(巴黎泛欧交易所:TNG)合作,正在与默沙东(默沙东公司,美国新泽西州拉威)的抗PD-1疗法KEYTRUDA(pembrolizumab)联合进行第10期研究,该公司是设计和开发病毒的生物技术公司基于免疫疗法的癌症治疗。
Details of the abstracts to be presented:
将要提交的摘要的详细信息:
Title: A Phase 1/2a First in-Human Phase 1 Study of BI-1910, a Monoclonal Antibody Agonistic to TNFR2, as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
标题:一项针对晚期实体瘤受试者的单克隆抗体 BI-1910(一种对 TNFR2 具有激动作用的单克隆抗体)的 1/2a 期首次人体 1 期研究
Authors: T. Hernandez Guerrero, B. Doger de Spéville, J. Yachnin, K. Rohrberg, M. Borggren, P. Holmkvist, I. Karlsson, M. Meller, L. Mårtensson, J.-A. Nilsson, M. Vaapil, M. Chisamore, J. Wallin, I. Teige, B. Frendeus, A. McAllister
作者:t. Hernandez Guerrero。Doger de Speíville,J. Yachninwan。Rohrbergwan。Borggren、P. Holmkvist、I. Karlsonvian。梅勒,L. Martensson,J.-A.Nilson万。Vaapil万。Chisamore、J. Wallin、I. Teige。弗伦德斯,A. 麦卡利斯特
Poster and Abstract# : 1073TiP
Session : Investigational immunotherapy
Date : September 14, 2024
海报和摘要编号:1073TiP
会议:研究性免疫疗法
日期:2024 年 9 月 14 日
Title: Initial Clinical Results Of BT-001, An Oncolytic Virus Expressing an Anti-CTLA-4 Mab, Administered as Single Agent and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors
标题:Bt-001是一种表达抗CTLA-4单抗的溶瘤病毒,以单一药物形式给药,与Pembrolizumab联合用于晚期实体瘤患者的初步临床结果
Authors: S. Champiat, C. Lebbe, J.-F. Baurain, A. Italiano, M. Sakkal, C. Spring-Giusti, N. Stojkowitz, M. Brandely, A. Sadoun, A. Ropenga, M. Semmrich, A. McAllister, M. Chisamore, P. Cassier
Poster and Abstract# : 1024P
Session : Investigational immunotherapy
Date : September 14, 2024
作者:S. Champiat、C. Lebbe、J.-F.Baurain,A. Italiano万。Sakkal、C. Spring-Giusti、N. Stojkowitzwan。Brandely、A. Sadoun、A. Ropengawan。Semmrich,A. McAllister万。P. Cassier Chisamore
海报和摘要编号:1024P
会议:研究性免疫疗法
日期:2024 年 9 月 14 日
The abstracts will be available on ESMO's website September 9, 2024, after 00:05 CEST.
这些摘要将在欧洲中部夏令时间2024年9月9日 00:05 之后在ESMO的网站上公布。
The posters will be posted to the Scientific Publications section of the company shortly after the presentations (website: )
这些海报将在演讲结束后不久发布到公司的科学出版物专区(网站:)
KEYTRUDA is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merk & Co., Inc., Rahway, NJ, USA.
KEYTRUDA是默沙东夏普和多姆有限责任公司的注册商标,默克公司是位于美国新泽西州拉威的默克公司的子公司。
About BioInvent
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently five drug candidates in six ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors. The Company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many promising new immune-modulatory candidates to fuel the Company's own clinical development pipeline and providing licensing and partnering opportunities.
关于 BioInvent
BioInvent International AB(纳斯达克斯德哥尔摩股票代码:BINV)是一家临床阶段的生物技术公司,致力于发现和开发用于癌症治疗的新型、同类首创的免疫调节抗体,目前在六个正在进行的治疗血液癌和实体瘤的临床项目中有五种候选药物。该公司经过验证的专有F.I.R.S.T技术平台可识别靶标和与其结合的抗体,从而产生许多有前途的新免疫调节候选药物,为公司自己的临床开发渠道提供动力,并提供许可和合作机会。
The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at Follow on the social media platform X: @BioInvent.
该公司的收入来自与多家顶级制药公司的研究合作和许可协议,以及为公司完全整合的制造部门中的第三方生产抗体。更多信息可在社交媒体平台的关注中获得 X: @BioInvent。
About Transgene
Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. Transgene's programs utilize viral vector technology with the goal of indirectly or directly killing cancer cells.
关于转基因
Transgene(泛欧交易所代码:TNG)是一家生物技术公司,专注于设计和开发治疗癌症的靶向免疫疗法。Transgene的项目利用病毒载体技术,目的是间接或直接杀死癌细胞。
The Company's clinical-stage programs consist of a portfolio of therapeutic vaccines and oncolytic viruses: TG4050, the first individualized therapeutic vaccine based on the myvac platform, TG4001 for the treatment of HPV-positive cancers, as well as BT-001 and TG6050, two oncolytic viruses based on the Invir.IO viral backbone. With Transgene's myvac platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. The myvac approach allows the generation of a virus-based immunotherapy that encodes patient-specific mutations identified and selected by Artificial Intelligence capabilities provided by its partner NEC. With its proprietary platform Invir.IO, Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses.
Additional information about Transgene is available at: Follow on social media: X (previously-Twitter): @TransgeneSA - LinkedIn: @Transgene
该公司的临床阶段项目包括一系列治疗性疫苗和溶瘤病毒:TG4050,第一种基于myvac平台的个性化治疗疫苗,用于治疗人乳头瘤病毒阳性癌症的 TG4001,以及基于Invir.io病毒主干的两种溶瘤病毒Bt-001和TG6050。借助Transgene的myvac平台,治疗性疫苗接种通过一种完全针对每个人量身定制的新型免疫疗法进入精准医学领域。myvac方法允许生成基于病毒的免疫疗法,该疗法对由其合作伙伴NEC提供的人工智能功能识别和选择的患者特异性突变进行编码。凭借其专有平台Invir.io,Transgene正在利用其病毒载体工程专业知识来设计新一代多功能溶瘤病毒。
有关 Transgene 的更多信息可在以下网址获得:在社交媒体上关注:X(之前是推特):@TransgeneSA-LinkedIn:@Transgene
For further information, please contact:
Cecilia Hofvander, Senior Director Investor Relations
Phone: +46 (0)46 286 85 50
Email: cecilia.hofvander@bioinvent.com
BioInvent International AB (publ)
Co. Reg. No. Org nr: 556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
欲了解更多信息,请联系:
塞西莉亚·霍夫凡德,投资者关系高级董事
电话:+46 (0) 46 286 85 50
电子邮件:cecilia.hofvander@bioinvent.com
BioInvent 国际实验室(publ)
Co.Reg。不是。组织编号:556537-7263
来访地址:Ideongatan 1
邮寄地址:223 70 LUND
电话:+46 (0) 46 286 85 50
The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.
新闻稿包含有关未来的声明,包括主观假设和对未来情景的预测。对未来的预测仅在做出日期时适用,就其本质而言,与生物技术领域的研发工作相同,与风险和不确定性有关。考虑到这一点,实际结果可能会与本新闻稿中描述的情景大相径庭。
Attachments
附件
BioInvent to Present Pipeline Progress on BI-1910 and BT-001 at ESMO
BioInvent 将在 ESMO 上介绍 BI-1910 和 Bt-001 的研发进展
SOURCE: BioInvent International
来源:生物发明国际